Oscar Health Inc expected to post a loss of 72 cents a share - Earnings Preview

Oscar Health

05/02/2024 21:42

* Oscar Health Inc  OSCR.N   OSCR.K  is expected to show a
rise in
quarterly revenue when it reports  results on February 7 for the
period ending December 31 2023
    * The New York City-based  company is expected to report a
42.7% increase in revenue to $1.42 billion from $995.13 million
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data. (SAL is on Total Revenue)
    * ​LSEG's mean analyst estimate for Oscar Health Inc is for
a loss
of 72 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Oscar
Health Inc
is $10.00​, below​ its last closing price of $13.64. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.47       -0.47      -0.29     Beat    38.6
 Jun. 30 2023  -0.22       -0.23      -0.07     Beat    69.6
 Mar. 31 2023  -0.04       -0.05      -0.18     Missed  -254.7
                                                        ​
 Dec. 31 2022  -1.09       -1.16      -1.05     Beat    9.5
 ​​Sep.        -0.72       -0.73      -0.91     Missed  -24.6
 30 2022                                                
 Jun. 30 2022  -0.51       -0.48      -0.53     Missed  -10.8​
 Mar. 31 2022  -0.21       -0.21      -0.36     Missed  -68.6
 Dec. 31 2021  -0.85       -0.96      -0.95     Beat    1.5
 This summary was machine generated February 5 at 21:42 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)